期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 12, 期 5, 页码 1092-1101出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2015.1129478
关键词
anti-CTL-A4; ipilimumab; immunotherapy; melanoma treatment; toxicity
In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据